This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cramer's 'Mad Money' Recap: West Pharma's Numbers in Safety

Click here for an archive of Cramer's "Mad Money" recaps.

"When you got a stock that's hitting its 52-week high while virtually everything else in its sector is snoozing ... that's something you need to take a look at," Jim Cramer told viewers of his "Mad Money" TV show Friday.

That's why he looked into West Pharmaceutical Services (WST - Get Report).

It's on top of the drug packaging and delivery markets, he said, and that means tamper-proof packaging, stoppers and seals. Unlike sexier pharmaceutical companies that make the drugs you read about, West Pharma is a dependable, boring stock that could make you some real money, he said.

The stock got its first boost in the 1980s, when Johnson & Johnson (JNJ) had to pull Tylenol off of shelves when cyanide was found in some tampered samples.

Now there's a new catalyst for the stock, he said, and it's Exubera, the new inhalable insulin.

He still likes Nektar Therapeutics (NKTR - Get Report) as a trade on the Exubera hoopla, because it created the delivery system for the treatment.

However, the stock is risky and he would sell it as soon as Exubera is released, he said.

But Nektar has outsourced the manufacturing of the inhaler to West Pharma, he said, making it a less risky way to play the "Exubera hoopla."

West Pharma has passed total cost increases on to customers, and "that's the kind of power you want stock to have," he said. The Lionville, Pa., company just beat first-quarter earnings estimates handily and guided up huge, added Cramer.

So with the stock flying high, is now a good time to buy? He said that if a stock is too expensive, he'll pass.

But West Pharma is trading at 17 times forward earnings on 27% growth, he said. So even though it has moved dramatically higher, it's still a cheap stock.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
IF $7.83 0.00%
NUVA $41.55 0.00%
NKTR $11.95 0.00%
TLK $43.38 0.00%
WST $55.58 0.00%


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs